Gene therapy and viral vaccination: the interface.
Live viral vaccines have had a major impact on the incidence of acute virus infections world-wide. Virus infections recognised as future vaccine targets will require a modified approach based on a detailed understanding of the immunobiology of specific infections combined with the application of new technologies designed to generate specific and appropriate protective immunity. A similar vector technology directed at in vivo gene delivery is currently being exploited both for gene therapy and vaccination. The induction of an immune response to an expressed transgene represents a potential hazard for a gene therapy protocol but is the object of a vaccine strategy. In vivo gene delivery using replication-competent or replication-deficient viral vector systems and by direct transfer of naked DNA can generate an effective humoral, secretory and cell-mediated immune response to expressed transgenes.
Wilkinson
G W
GW
Department of Medicine, University of Wales College of Medicine, Cardiff, UK.
Borysiewicz
L K
LK
D000256:Adenoviridae / Q000276:immunology*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D012190:Retroviridae / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines / Q000627:therapeutic use*
D014614:Vaccines, Synthetic; D014765:Viral Vaccines